ANI Pharmaceuticals, Inc. $ANIP Shares Purchased by Nomura Holdings Inc.

Key Points

• Nomura Holdings Inc. increased its stake in ANI Pharmaceuticals by 1.5% in the first quarter, holding 1.00% of the company worth approximately $14.54 million.
• Corporate insiders sold 405,538 shares of ANI Pharmaceuticals stock worth around $35.69 million in the last quarter, indicating significant insider trading activity.
• ANI Pharmaceuticals' quarterly earnings report showed a positive earnings per share of $1.80, surpassing analyst expectations and reflecting a 53.2% revenue increase year-over-year.

Nomura Holdings Inc. grew its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 1.5% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 217,176 shares of the specialty pharmaceutical company's stock after buying an additional 3,297 shares during the quarter. Nomura Holdings Inc. owned 1.00% of ANI Pharmaceuticals worth $14,540,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of ANIP. National Bank of Canada FI acquired a new position in shares of ANI Pharmaceuticals in the 1st quarter valued at about $79,000. GAMMA Investing LLC lifted its holdings in shares of ANI Pharmaceuticals by 163.8% in the 1st quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock valued at $95,000 after buying an additional 881 shares during the period. Rafferty Asset Management LLC acquired a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at about $200,000. Bridgefront Capital LLC acquired a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at about $204,000. Finally, Mesirow Financial Investment Management Inc. acquired a new position in shares of ANI Pharmaceuticals in the 1st quarter valued at about $206,000. Institutional investors and hedge funds own 76.05% of the company's stock.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 52,988 shares of the business's stock in a transaction that occurred on Thursday, August 21st. The stock was sold at an average price of $90.44, for a total transaction of $4,792,234.72. Following the completion of the sale, the chief operating officer directly owned 431,920 shares in the company, valued at approximately $39,062,844.80. The trade was a 10.93% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Matthew J. Leonard sold 2,528 shares of the business's stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $90.62, for a total value of $229,087.36. Following the sale, the director owned 6,864 shares of the company's stock, valued at approximately $622,015.68. This trade represents a 26.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 405,538 shares of company stock worth $35,690,131 in the last quarter. Corporate insiders own 12.70% of the company's stock.

ANI Pharmaceuticals Price Performance

Shares of ANI Pharmaceuticals stock opened at $93.50 on Monday. The company has a quick ratio of 1.96, a current ratio of 2.54 and a debt-to-equity ratio of 1.39. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $93.72. The business has a 50-day moving average price of $73.39 and a 200 day moving average price of $67.12. The firm has a market cap of $2.03 billion, a PE ratio of -121.43 and a beta of 0.63.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.38. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The firm had revenue of $211.37 million during the quarter, compared to analyst estimates of $187.18 million. During the same quarter in the previous year, the business earned $1.02 EPS. ANI Pharmaceuticals's revenue for the quarter was up 53.2% compared to the same quarter last year. Sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ANIP. Zacks Research raised ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 21st. Guggenheim reissued a "buy" rating and issued a $86.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Piper Sandler reissued an "overweight" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Wall Street Zen upgraded ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 16th. Finally, Truist Financial lifted their price target on ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a "hold" rating in a research note on Monday, August 11th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of "Buy" and an average target price of $84.75.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.